Overview

Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis

Status:
Completed
Trial end date:
2014-04-13
Target enrollment:
0
Participant gender:
All
Summary
To investigate the safety and efficacy of the administration of Iguratimod (CRM01T) for 52 weeks in patients with rheumatoid arthritis in clinical practice
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Eisai Co., Ltd.
Criteria
Inclusion criteria

- Participants with rheumatoid arthritis

- Participants who take iguratimod

Exclusion criteria

- Participants registered for this survey previously

- Pregnant women or women suspected of being pregnant

- Participants with a serious liver disorder

- Participants with peptic ulcer

- Participants with known hypersensitivity to iguratimod or any of its excipients